Chemotherapy-related cardiotoxicity: are Australian practitioners missing the point?

Internal Medicine Journal

Volumn 47, Issue 10, 2017, Pages 1166-1172

  Conyers, Rachel ^a   Costello, Ben ^b   La Gerche, Andre ^b   Tripaydonis, Anne ^c   Burns, Charlotte ^a   Ludlow, Louise ^d   Lange, Peter ^e   Ekert, Paul ^a   Mechinaud, Francoise ^a   Cheung, Michael ^a   Martin, Michelle ^a   Elliot, David ^d  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

adolescent and young adults; anthracycline cardiotoxicity; cancer; cardio oncology; childhood cancer; echocardiography; late onset cardiotoxicity

Indexed keywords

DAUNORUBICIN; DOXORUBICIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARDIOTOXIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR PARAMETERS; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; EWING SARCOMA; FEMALE; FOLLOW UP; FRACTIONAL SHORTENING; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; CLINICAL AUDIT; DIAGNOSTIC IMAGING; INFANT; PHYSICIAN; PRESCHOOL CHILD; STANDARDS; TRENDS; YOUNG ADULT;

ADOLESCENT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; AUSTRALIA; CARDIOTOXICITY; CARDIOTOXINS; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; MALE; MEDICAL AUDIT; PHYSICIANS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85030658438     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.13481     Document Type: Article

References (32)

1. Brower V. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer. J Natl Cancer Inst 2013; 105: 835–6.
2. Hensen KE, Reulen RC, Winter DL, Bright CJ, Fidler MM, Frobisher C et al. Cardiac mortality among 200,000 five-year survivors of cancer diagnosed 15–39 years: the Teenage and Young Adult Cancer Survivor study. Circulation 2016; 134: 1519–31.
3. Felker GM, Thompson RE, Hare JM. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342: 1077–84.
4. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 2011; 13: R64.
5. Van der Pal HJ, van Dalen EC, van Delden E, Van Dijk IW, Kok WE, Geskus RB et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 2012; 30: 1429–37.
6. Kremer LC, van der Pal HJ, Offringa M, Van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002; 13: 819–29.
7. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672–7.
8. Marwick AB, Rowland JH, Yabroff KR, Scoppa S, Hachey M, Ries L et al. Long-term survivors of childhood cancers in the United States.
9. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572–82.
10. Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL et al. Late mortality among 5-year survivors of childhood cancer: a summary from the childhood cancer survivor study. J Clin Oncol 2009; 27: 2378–38.
11. Mulrooney DA, Armstrong GT, Huang S, Ness KK, Ehrhardt MJ, Joshi VM et al. Cardiac outcomes in adult survivors of childhood cancer exposed to cardiotoxic therapy: a cross-sectional study. Ann Intern Med 2016; 164: 93–101.
12. Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 2013; 128: 1927–95.
13. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009; 339: b4606.
14. Van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer 2006; 42: 3191–8.
15. Landier W, Bhatia S, Eshelman DA, Forte KJ, Sweeney T, Hester AL et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22: 4979–90.
16. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Society of Cardiovascular imaging. Eur Heart J Cardiovasc Imaging 2014; 15: 1063–93.
17. Armenian S, Hudson M, Mulder R, Chen M, Constine L, Dwyer M et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015; 16: e123–36.
18. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: e1–90.
19. Nathan PC, Greenberg ML, Ness KK, Hudson MM, Mertens AC, Mahoney MC et al. Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2008; 26: 4401–9.
20. Kadan-Lottick NS, Robison LL, Gurney JG, Neglia JP, Yasui Y, Hayashi R et al. Childhood cancer survivors’ knowledge about their past diagnosis and treatment: Childhood Cancer Survivor Study. JAMA 2002; 287: 1832–9.
21. McGuire WP, Rowinksy EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273–99.
22. Simbre VC, Duffy SA, Dadlani GH, Miller TL, Lipshultz SE. Cardiotoxicity of cancer chemotherapy: implications for children. Paediatr Drugs 2005; 7: 187–202.
23. Huang SY, Chang CS, Tang JL, Tien HF, Kuo TL, Huang SF et al. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 1998; 103: 1092–5.
24. Kandylis K, Vassilomanolakis M, Tsoussis S, Efremidis AP. Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol 1989; 24: 395–6.
25. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis and management. J Am Coll Cardiol 2009; 53: 2231–47.
26. Bagnes C, Panchuk PN, Recondo G. Antineoplastic chemotherapy inducted QTc prolongation. Curr Drug Saf 2010; 5: 93–6.
27. Albini A, Pennesi G, Donatelli F, Cammarota R, De Fiora S, Noonan DM. Cardiotoxicity of anticancer drugs – the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010; 102: 14–25.
28. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2008; 100: 685.
29. Escudier B, Eisen T, Stadler WM, Sczczylik C, Oudard S, Siebels M et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 357: 203.
30. Zhou J, Zhang Y, Li J, Li X, Hou J, Zhao Y et al. Single agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukaemia. Blood 2010; 115: 1697–702.
31. Khakoo AY, Kassiotis CM. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008; 1112: 2500–8.
32. Perez EA, Rodsheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004; 22: 322–9.